Stem Cell/iPSC Therapies Poised to Transform Parkinson’s Disease Treatment: Multiple Chinese Biotechs Advance Clinical Pipelines

　　【Pharmaceutical Network Industry Dynamics】Parkinson's disease is a common neurodegenerative disorder, with main symptoms including resting tremors, bradykinesia, and muscle rigidity. It is reported that stem cell/iPSC (induced pluripotent stem cell) therapy, with its unique advantages, has brought new hope for the treatment of Parkinson’s disease. Numerous companies in China have been actively investing in this cutting-edge field, sparking a wave of innovative treatment research and development.
 

Among them, iRegene's NouvNeu001 is a chemically induced human dopaminergic neuronal precursor that relies on an advanced induced pluripotent stem cell (iPSC) technology platform. It uses iPSC as the "seed" to culture and obtain healthy dopaminergic neural precursor cells. These cells are then implanted into the lesion area to compensate for the missing dopaminergic neurons. In addition to secreting dopamine, a neurotransmitter, these precursor cells can further secrete various proteins and small nucleic acids, providing a favorable "soil" environment for the transplanted cells to function effectively in the brain. This enhances the improvement of the original lesion by the transplanted cells, achieving comprehensive therapeutic effects. It was reported that on December 19, the Phase I/III clinical study of the NouvNeu001 injection had been initiated. On December 22, the NouvNeu001 injection received the Regenerative Medicine Advanced Therapy (RMAT) designation granted by the FDA.
 

NCR201 from Anhui Zhongsheng Traceability Biotechnology Co., Ltd. is an iPSC-derived dopaminergic neural precursor cell (iDAP) product. Through years of technical optimization and innovative breakthroughs, the company has successfully developed a universal and highly efficient iDAP cell therapy with significant advantages in clinical applicability and treatment accessibility, offering a revolutionary treatment option for Parkinson's disease patients. NCR201 uses iPSC as the source seed cell, not only possessing the basic advantages of large-scale mass production and high batch-to-batch consistency typical of iPSC-derived cell therapies, but also reaching an advanced level in the core metric of cell purity. It was reported that on December 22, the Phase I/II clinical trial assessing the safety, tolerability, and preliminary efficacy of the NCR201 injection for treating Parkinson’s disease (PD) had been initiated.
 

XsellSmart's XS411 Injection is an innovative, allogeneic, "off-the-shelf" iPSC-derived dopaminergic neural progenitor cell therapeutic drug (Clinical GMP grade, Class I New Drug in China) developed independently by the company. In April 2025, the Investigational New Drug (IND) application for this drug was officially approved by the National Medical Products Administration (NMPA), marking its official entry into the clinical trial phase for Parkinson's disease treatment.
 

UniXelI BIOTECHNOLOGY Independently Developed UX-DA001, a Midbrain Dopaminergic Neuronal Progenitor Cell Drug for the Treatment of Parkinson's Disease. This drug, which has been approved for clinical trials in both China and the U.S., is an iPSC-derived autologous cell therapy for Parkinson’s disease. It is prepared by reprogramming and differentiating peripheral blood cells from the patient and administered via minimally invasive surgery to transplant autologous induced pluripotent stem cell (iPSC)-differentiated dopaminergic neuronal progenitor cells into the brain. Patients receiving this treatment do not require immunosuppressants, thereby reducing the risk of immune-related side effects. Additionally, UX-DA001 is expected to reconstruct the severely affected neural networks in Parkinson’s patients and restore their motor and non-motor functions, improving their quality of life.
 

It is reported that against the backdrop of an increasingly aging global population, Parkinson's disease, a common degenerative disorder of the central nervous system, is causing suffering for a growing number of patients. Statistics show that the prevalence of Parkinson's disease among people aged 65 and above in China is 1.63%. With the intensification of population aging, it is expected that by 2030, the number of Parkinson's patients in China will exceed 5 million, indicating a huge demand for drug therapies. As multiple candidate drugs progress through clinical trials, stem cell/iPSC therapies are expected to achieve clinical translation within the next few years, offering new treatment options for patients with Parkinson's disease.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.